It will be several years before it is known what the benefits of such therapy are and which patients should be considered for it. A careful discussion with each patient is appropriate.
Adjuvant therapy with chemotherapy for estrogen-receptor-negative patients and tamoxifen for estrogen-receptor-positive patients usually begins within four to six weeks of surgery. There are several effective programs, with other drug combinations and hormonal therapies under clinical evaluation.
